Healthcare / Pharmaceutical RetailersNasdaqCM
$3.85
+0.43 (+12.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-1.6M · quality 63.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
813.6%
↑Gross Margin
-27.5%
↓Debt/Equity
-1.99
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.7%
FCF CAGR
—
FCF margin
-50.3%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $23.3M · net income $-101.3M · FCF $-11.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $23.3M | $23.3M | $18.1M | — | $32.8M |
| Net Income | $-101.3M | $-101.3M | $-6.9M | $-2.9M | $-2.7M |
| EBITDA | $-93.5M | $-93.5M | $-4.9M | $-2.9M | $-369034.00 |
| EPS | — | — | -0.15 | -0.06 | -0.06 |
| Gross Margin | -27.5% | -27.5% | 9.7% | — | 17.5% |
| Operating Margin | -347.9% | -347.9% | -33.9% | — | -10.4% |
| Net Margin | -433.9% | -433.9% | -37.8% | — | -8.4% |
| Balance Sheet | |||||
| Debt/Equity | -1.99 | -1.99 | 3.73 | -0.12 | — |
| Current Ratio | 0.09 | 0.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.7M | $-11.7M | $-1.6M | $-349136.00 | — |
| Returns | |||||
| ROE | 813.6% | 813.6% | -101.8% | 99.8% | 52262.9% |
| Growth & Yield | |||||
| Revenue Growth | 28.7% | 28.7% | — | — | — |
| EPS Growth | — | — | -150.0% | -3.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-96.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.15 → n/d
Residual
-96.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.